Effect of VExUS Score on Postoperative Pulmonary Complications in Elderly Patients
Starting soon
Conditions studied: Esophageal Cancer (EsC), Postoperative Pulmonary Complications (PPCs)
In brief
Brief Summary This clinical trial aims to evaluate whether perioperative goal-directed fluid therapy (GDFT) targeting a venous excess ultrasound (VExUS) score of 1 can reduce postoperative pulmonary complications (PPCs) in elderly patients undergoing McKeown minimally invasive esophagectomy (MIE). The study will also assess postoperative organ microcirculatory perfusion and quality of recovery. Key research questions the trial seeks to answer include: Does VExUS score-guided GDFT reduce the incidence of PPCs in elderly patients following McKeown MIE? Do participants receiving VExUS-guided GDFT achieve better clinical outcomes? Investigators will compare VExUS score-targeted GDFT with fluid therapy guided by the standard Vigileo-FloTrac™ system, to determine if the VExUS-guided approach reduces the occurrence of postoperative pulmonary complications in elderly patients. Participant assessments and data collection include: VExUS score assessment at four time points: preoperatively, after thoracic phase of surgery, after abdominal phase of surgery, and at the end of surgery. Concomitant measurements will include capillary refill time (CRT, in minutes), perfusion index (PI), blood lactate level (Lac, in mmol/L), and central venous oxygen saturation (ScvO₂, in percent). Postoperative lung ultrasound score assessment. Recording of clinical outcomes including length of intensive care unit (ICU) stay (in days), postoperative hospital length of stay (in days), 30-day postoperative readmission rate due to pulmonary complications (in percent), and in-hospital postoperative mortality rate (in percent).
Key facts
- Study ID
- NCT07691944
- Run by
- First Affiliated Hospital of Chongqing Medical University
- People needed
- 126
- Starts
- 2026-08-01
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-07-09
Who can join
Age: 65 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age between 65 and 80 years old
- Scheduled for elective McKeown MIE
- ASA physical status classification I to III
- Body mass index (BMI) between 18 kg/m² and 30 kg/m² (exclusive of 18 kg/m²)
You may not qualify if…
- Respiratory failure (SaO₂ < 60 mmHg and/or PaCO₂ > 50 mmHg)
- Severe cardiac dysfunction (NYHA class III-IV)
- Angina pectoris within the past 3 months or acute myocardial infarction (STEMI/NSTEMI) within the past 6 months
- Pulmonary hypertension (pulmonary artery systolic pressure, PASP > 35 mmHg)
- Moderate to severe tricuspid stenosis/regurgitation (valve orifice area < 1.5 cm² / vena contracta width ≥ 0.3 cm)
- Decompensated cirrhosis (Child-Pugh class ≥ B)
- Chronic kidney disease (CKD stage ≥ 3a) (estimated glomerular filtration rate, eGFR < 45 mL/min/1.73 m²)
- Cognitive impairment (Mini-Mental State Examination, MMSE < 27) and inability to cooperate with follow-up
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.